JP2018528270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528270A5 JP2018528270A5 JP2018532811A JP2018532811A JP2018528270A5 JP 2018528270 A5 JP2018528270 A5 JP 2018528270A5 JP 2018532811 A JP2018532811 A JP 2018532811A JP 2018532811 A JP2018532811 A JP 2018532811A JP 2018528270 A5 JP2018528270 A5 JP 2018528270A5
- Authority
- JP
- Japan
- Prior art keywords
- carbonyl
- propoxy
- amino
- piperidyl
- oxotetrahydrofuran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 2,2,2-trifluoroacetyl Chemical group 0.000 claims description 184
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 105
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 104
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims description 86
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 47
- 150000001875 compounds Chemical class 0.000 claims description 15
- CSTKIGPTGZCTBG-KNBMTAEXSA-N (3S)-3-[[5-[(1R,2S)-1-(4-methylphenyl)-2-[(2,2,2-trifluoroacetyl)amino]propoxy]pyridine-2-carbonyl]amino]piperidine-1-carboxylic acid Chemical compound C[C@H](NC(=O)C(F)(F)F)[C@H](Oc1ccc(nc1)C(=O)N[C@H]1CCCN(C1)C(O)=O)c1ccc(C)cc1 CSTKIGPTGZCTBG-KNBMTAEXSA-N 0.000 claims description 12
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 8
- XAGGWTGPHUHROT-ARBPTSGCSA-N C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)[C@@H]1OCCC1)OC1=CC=C(C(=O)O)C=C1 Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)[C@@H]1OCCC1)OC1=CC=C(C(=O)O)C=C1 XAGGWTGPHUHROT-ARBPTSGCSA-N 0.000 claims description 7
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 6
- YNZKXOLUEFVOMR-LRDDRELGSA-N C1(=CC=C(C=C1)[C@H]([C@H](C)NC(C(F)(F)F)=O)OC1=CC=C(C(=O)O)C=C1)C Chemical compound C1(=CC=C(C=C1)[C@H]([C@H](C)NC(C(F)(F)F)=O)OC1=CC=C(C(=O)O)C=C1)C YNZKXOLUEFVOMR-LRDDRELGSA-N 0.000 claims description 5
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- PHTRJJLCDJBNJV-DJJJIMSYSA-N 4-[(1R,2S)-1-(4-cyclopropylphenyl)-2-(1,2,4-oxadiazole-3-carbonylamino)propoxy]benzoic acid Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C1=NOC=N1)OC1=CC=C(C(=O)O)C=C1 PHTRJJLCDJBNJV-DJJJIMSYSA-N 0.000 claims description 3
- XHNACPWIVCHUDW-RBZFPXEDSA-N 4-[(1R,2S)-1-(4-cyclopropylphenyl)-2-(1,2,5-thiadiazole-3-carbonylamino)propoxy]benzoic acid Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C1=NSN=C1)OC1=CC=C(C(=O)O)C=C1 XHNACPWIVCHUDW-RBZFPXEDSA-N 0.000 claims description 3
- SSYQSSZKIANTFW-QKKBWIMNSA-N 4-[(1R,2S)-1-(4-cyclopropylphenyl)-2-(1,2-thiazole-3-carbonylamino)propoxy]benzoic acid Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C1=NSC=C1)OC1=CC=C(C(=O)O)C=C1 SSYQSSZKIANTFW-QKKBWIMNSA-N 0.000 claims description 3
- AUSFRQACCFCLTD-QKKBWIMNSA-N 4-[(1R,2S)-1-(4-cyclopropylphenyl)-2-(1,2-thiazole-5-carbonylamino)propoxy]benzoic acid Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C1=CC=NS1)OC1=CC=C(C(=O)O)C=C1 AUSFRQACCFCLTD-QKKBWIMNSA-N 0.000 claims description 3
- ZDEWPLFDUDYPNV-XOBRGWDASA-N 4-[(1R,2S)-1-(4-cyclopropylphenyl)-2-(1,3-oxazole-2-carbonylamino)propoxy]benzoic acid Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C=1OC=CN=1)OC1=CC=C(C(=O)O)C=C1 ZDEWPLFDUDYPNV-XOBRGWDASA-N 0.000 claims description 3
- CDJMBJPRFSZLQD-QKKBWIMNSA-N 4-[(1R,2S)-1-(4-cyclopropylphenyl)-2-(1,3-oxazole-5-carbonylamino)propoxy]benzoic acid Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C1=CN=CO1)OC1=CC=C(C(=O)O)C=C1 CDJMBJPRFSZLQD-QKKBWIMNSA-N 0.000 claims description 3
- UFDCSZBCVJNTCV-QKKBWIMNSA-N 4-[(1R,2S)-1-(4-cyclopropylphenyl)-2-(1,3-thiazole-4-carbonylamino)propoxy]benzoic acid Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C=1N=CSC=1)OC1=CC=C(C(=O)O)C=C1 UFDCSZBCVJNTCV-QKKBWIMNSA-N 0.000 claims description 3
- DZBRJMKJPFDAAD-QKKBWIMNSA-N 4-[(1R,2S)-1-(4-cyclopropylphenyl)-2-(1,3-thiazole-5-carbonylamino)propoxy]benzoic acid Chemical compound C[C@@H]([C@@H](C1=CC=C(C=C1)C2CC2)OC3=CC=C(C=C3)C(=O)O)NC(=O)C4=CN=CS4 DZBRJMKJPFDAAD-QKKBWIMNSA-N 0.000 claims description 3
- UUIFVMOJPQAWCR-DJJJIMSYSA-N 4-[(1R,2S)-1-(4-cyclopropylphenyl)-2-(2,2-difluoropropanoylamino)propoxy]benzoic acid Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(C(C)(F)F)=O)OC1=CC=C(C(=O)O)C=C1 UUIFVMOJPQAWCR-DJJJIMSYSA-N 0.000 claims description 3
- ISJJRILLNCVSIV-NYHFZMIOSA-N 4-[(1R,2S)-1-(4-cyclopropylphenyl)-2-[(1-methylimidazole-4-carbonyl)amino]propoxy]benzoic acid Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C=1N=CN(C=1)C)OC1=CC=C(C(=O)O)C=C1 ISJJRILLNCVSIV-NYHFZMIOSA-N 0.000 claims description 3
- WAWKZFBBPNQPEZ-NYHFZMIOSA-N 4-[(1R,2S)-1-(4-cyclopropylphenyl)-2-[(1-methylpyrazole-3-carbonyl)amino]propoxy]benzoic acid Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C1=NN(C=C1)C)OC1=CC=C(C(=O)O)C=C1 WAWKZFBBPNQPEZ-NYHFZMIOSA-N 0.000 claims description 3
- VWASKTKDXREJKS-SGTLLEGYSA-N 4-[(1R,2S)-1-(4-cyclopropylphenyl)-2-[(2,2,2-trifluoroacetyl)amino]propoxy]benzoic acid Chemical compound C[C@@H]([C@@H](C1=CC=C(C=C1)C2CC2)OC3=CC=C(C=C3)C(=O)O)NC(=O)C(F)(F)F VWASKTKDXREJKS-SGTLLEGYSA-N 0.000 claims description 3
- XJNISERPXDAJHI-QKKBWIMNSA-N 4-[(1R,2S)-1-(4-cyclopropylphenyl)-2-[(2-methoxyacetyl)amino]propoxy]benzoic acid Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(COC)=O)OC1=CC=C(C(=O)O)C=C1 XJNISERPXDAJHI-QKKBWIMNSA-N 0.000 claims description 3
- IHALRUPWMIWTMZ-FPTDNZKUSA-N 4-[(1R,2S)-1-(4-cyclopropylphenyl)-2-[(2-methyl-1,3-thiazole-5-carbonyl)amino]propoxy]benzoic acid Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C1=CN=C(S1)C)OC1=CC=C(C(=O)O)C=C1 IHALRUPWMIWTMZ-FPTDNZKUSA-N 0.000 claims description 3
- HBJJZSZVCYFYOL-NYHFZMIOSA-N 4-[(1R,2S)-1-(4-cyclopropylphenyl)-2-[(2-methylpyrazole-3-carbonyl)amino]propoxy]benzoic acid Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C=1N(N=CC=1)C)OC1=CC=C(C(=O)O)C=C1 HBJJZSZVCYFYOL-NYHFZMIOSA-N 0.000 claims description 3
- HVYJMCBFHYHWHS-QKKBWIMNSA-N 4-[(1R,2S)-1-(4-cyclopropylphenyl)-2-[(4-methyl-1,2,5-oxadiazole-3-carbonyl)amino]propoxy]benzoic acid Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C1=NON=C1C)OC1=CC=C(C(=O)O)C=C1 HVYJMCBFHYHWHS-QKKBWIMNSA-N 0.000 claims description 3
- AAFZTQCBAVIDEO-BTYIYWSLSA-N 4-[(1R,2S)-1-(4-cyclopropylphenyl)-2-[(4-methyl-1,3-oxazole-5-carbonyl)amino]propoxy]benzoic acid Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C1=C(N=CO1)C)OC1=CC=C(C(=O)O)C=C1 AAFZTQCBAVIDEO-BTYIYWSLSA-N 0.000 claims description 3
- KAZPCJHNYAELIL-QKKBWIMNSA-N 4-[(1R,2S)-1-(4-cyclopropylphenyl)-2-[(4-methyl-1,3-thiazole-5-carbonyl)amino]propoxy]benzoic acid Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C1=C(N=CS1)C)OC1=CC=C(C(=O)O)C=C1 KAZPCJHNYAELIL-QKKBWIMNSA-N 0.000 claims description 3
- RZOSUILBAKRSOV-RBZFPXEDSA-N 4-[(1R,2S)-1-(4-cyclopropylphenyl)-2-[(4-methylthiadiazole-5-carbonyl)amino]propoxy]benzoic acid Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C1=C(N=NS1)C)OC1=CC=C(C(=O)O)C=C1 RZOSUILBAKRSOV-RBZFPXEDSA-N 0.000 claims description 3
- XPWVJEWEYCRWOZ-FPTDNZKUSA-N 4-[(1R,2S)-1-(4-cyclopropylphenyl)-2-[(5-methyl-1,2-thiazole-4-carbonyl)amino]propoxy]benzoic acid Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C=1C=NSC=1C)OC1=CC=C(C(=O)O)C=C1 XPWVJEWEYCRWOZ-FPTDNZKUSA-N 0.000 claims description 3
- VRELQKPRQCFZHL-RBZFPXEDSA-N 4-[(1R,2S)-1-(4-cyclopropylphenyl)-2-[(5-methyl-1,3,4-oxadiazole-2-carbonyl)amino]propoxy]benzoic acid Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C=1OC(=NN=1)C)OC1=CC=C(C(=O)O)C=C1 VRELQKPRQCFZHL-RBZFPXEDSA-N 0.000 claims description 3
- MSYNBEJJRXNQRP-BTYIYWSLSA-N 4-[(1R,2S)-1-(4-cyclopropylphenyl)-2-[(5-methyl-1,3-thiazole-2-carbonyl)amino]propoxy]benzoic acid Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C=1SC(=CN=1)C)OC1=CC=C(C(=O)O)C=C1 MSYNBEJJRXNQRP-BTYIYWSLSA-N 0.000 claims description 3
- PRWOFYBABSRYEC-FPTDNZKUSA-N 4-[(1R,2S)-1-(4-cyclopropylphenyl)-2-[(5-methyl-1,3-thiazole-4-carbonyl)amino]propoxy]benzoic acid Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C=1N=CSC=1C)OC1=CC=C(C(=O)O)C=C1 PRWOFYBABSRYEC-FPTDNZKUSA-N 0.000 claims description 3
- GEPKLMUNEAXBOB-RBZFPXEDSA-N C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C1=NC(=NO1)C)OC1=CC=C(C(=O)O)C=C1 Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C1=NC(=NO1)C)OC1=CC=C(C(=O)O)C=C1 GEPKLMUNEAXBOB-RBZFPXEDSA-N 0.000 claims description 3
- BHMUBRPNKUHCBC-NYHFZMIOSA-N C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C1=NOC(=C1)C)OC1=CC=C(C(=O)O)C=C1 Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C1=NOC(=C1)C)OC1=CC=C(C(=O)O)C=C1 BHMUBRPNKUHCBC-NYHFZMIOSA-N 0.000 claims description 3
- DYBKHMOJIYYBCE-QKKBWIMNSA-N C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C1=NOC=C1)OC1=CC=C(C(=O)O)C=C1 Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C1=NOC=C1)OC1=CC=C(C(=O)O)C=C1 DYBKHMOJIYYBCE-QKKBWIMNSA-N 0.000 claims description 3
- GHGZWGIKJKJSSV-ZSOQJEKZSA-N C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C1=NOC=C1)OC=1C=NC(=CC=1)C(N[C@@H]1CN(CCC1)C(=O)[C@H]1COC(C1)=O)=O Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C1=NOC=C1)OC=1C=NC(=CC=1)C(N[C@@H]1CN(CCC1)C(=O)[C@H]1COC(C1)=O)=O GHGZWGIKJKJSSV-ZSOQJEKZSA-N 0.000 claims description 3
- PJISKUVUGXYKLP-RBZFPXEDSA-N C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C=1N=NSC=1)OC1=CC=C(C(=O)O)C=C1 Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C=1N=NSC=1)OC1=CC=C(C(=O)O)C=C1 PJISKUVUGXYKLP-RBZFPXEDSA-N 0.000 claims description 3
- RJJDMHLHZODAGD-NYHFZMIOSA-N C[C@@H]([C@@H](C1=CC=C(C2CC2)C=C1)OC(C=C1)=CC=C1C(O)=O)NC(C1=CC(C)=NO1)=O Chemical compound C[C@@H]([C@@H](C1=CC=C(C2CC2)C=C1)OC(C=C1)=CC=C1C(O)=O)NC(C1=CC(C)=NO1)=O RJJDMHLHZODAGD-NYHFZMIOSA-N 0.000 claims description 3
- XUYPCUBVQFPGAA-QKKBWIMNSA-N C[C@@H]([C@@H](C1=CC=C(C2CC2)C=C1)OC(C=C1)=CC=C1C(O)=O)NC(C1=CC=NO1)=O Chemical compound C[C@@H]([C@@H](C1=CC=C(C2CC2)C=C1)OC(C=C1)=CC=C1C(O)=O)NC(C1=CC=NO1)=O XUYPCUBVQFPGAA-QKKBWIMNSA-N 0.000 claims description 3
- YFKCACXEVIUVCH-QKKBWIMNSA-N C[C@@H]([C@@H](C1=CC=C(C2CC2)C=C1)OC(C=C1)=CC=C1C(O)=O)NC(C1=CN=NN1C)=O Chemical compound C[C@@H]([C@@H](C1=CC=C(C2CC2)C=C1)OC(C=C1)=CC=C1C(O)=O)NC(C1=CN=NN1C)=O YFKCACXEVIUVCH-QKKBWIMNSA-N 0.000 claims description 3
- WCXCBVLNQNGCND-NYHFZMIOSA-N C[C@@H]([C@@H](C1=CC=C(C2CC2)C=C1)OC(C=C1)=CC=C1C(O)=O)NC(C1=CON=C1C)=O Chemical compound C[C@@H]([C@@H](C1=CC=C(C2CC2)C=C1)OC(C=C1)=CC=C1C(O)=O)NC(C1=CON=C1C)=O WCXCBVLNQNGCND-NYHFZMIOSA-N 0.000 claims description 3
- WJTAMSICAKJLJI-RBZFPXEDSA-N C[C@@H]([C@@H](C1=CC=C(C2CC2)C=C1)OC(C=C1)=CC=C1C(O)=O)NC(C1=NOC(C)=N1)=O Chemical compound C[C@@H]([C@@H](C1=CC=C(C2CC2)C=C1)OC(C=C1)=CC=C1C(O)=O)NC(C1=NOC(C)=N1)=O WJTAMSICAKJLJI-RBZFPXEDSA-N 0.000 claims description 3
- GAZXVGIXYAIKSU-XOBRGWDASA-N C[C@@H]([C@@H](C1=CC=C(C=C1)C2CC2)OC3=CC=C(C=C3)C(=O)O)NC(=O)C4=NC=CS4 Chemical compound C[C@@H]([C@@H](C1=CC=C(C=C1)C2CC2)OC3=CC=C(C=C3)C(=O)O)NC(=O)C4=NC=CS4 GAZXVGIXYAIKSU-XOBRGWDASA-N 0.000 claims description 3
- XAGGWTGPHUHROT-RXYZOABWSA-N C[C@@H]([C@@H](C1=CC=C(C=C1)C2CC2)OC3=CC=C(C=C3)C(=O)O)NC(=O)[C@@H]4CCCO4 Chemical compound C[C@@H]([C@@H](C1=CC=C(C=C1)C2CC2)OC3=CC=C(C=C3)C(=O)O)NC(=O)[C@@H]4CCCO4 XAGGWTGPHUHROT-RXYZOABWSA-N 0.000 claims description 3
- PJJSDXBTBTXDOM-ZSOQJEKZSA-N N-[(1R,2S)-1-(4-cyclopropylphenyl)-1-[6-[[(3S)-1-[(3R)-5-oxooxolane-3-carbonyl]piperidin-3-yl]carbamoyl]pyridin-3-yl]oxypropan-2-yl]-1,2-oxazole-5-carboxamide Chemical compound C[C@H](NC(=O)c1ccno1)[C@H](Oc1ccc(nc1)C(=O)N[C@H]1CCCN(C1)C(=O)[C@H]1COC(=O)C1)c1ccc(cc1)C1CC1 PJJSDXBTBTXDOM-ZSOQJEKZSA-N 0.000 claims description 3
- DKAQKHMZLKTOLF-ZSOQJEKZSA-N N-[(1R,2S)-1-(4-cyclopropylphenyl)-1-[6-[[(3S)-1-[(3R)-5-oxooxolane-3-carbonyl]piperidin-3-yl]carbamoyl]pyridin-3-yl]oxypropan-2-yl]-1,2-thiazole-3-carboxamide Chemical compound S1N=C(C=C1)C(=O)N[C@H]([C@H](OC=1C=NC(=CC=1)C(N[C@@H]1CN(CCC1)C(=O)[C@H]1COC(C1)=O)=O)C1=CC=C(C=C1)C1CC1)C DKAQKHMZLKTOLF-ZSOQJEKZSA-N 0.000 claims description 3
- DVSUJVFDKPDVPK-ZSOQJEKZSA-N N-[(1R,2S)-1-(4-cyclopropylphenyl)-1-[6-[[(3S)-1-[(3R)-5-oxooxolane-3-carbonyl]piperidin-3-yl]carbamoyl]pyridin-3-yl]oxypropan-2-yl]-1,2-thiazole-5-carboxamide Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C1=CC=NS1)OC=1C=NC(=CC=1)C(N[C@@H]1CN(CCC1)C(=O)[C@H]1COC(C1)=O)=O DVSUJVFDKPDVPK-ZSOQJEKZSA-N 0.000 claims description 3
- WXZCDISWKXRJCU-FRLNKARYSA-N N-[(1R,2S)-1-(4-cyclopropylphenyl)-1-[6-[[(3S)-1-[(3R)-5-oxooxolane-3-carbonyl]piperidin-3-yl]carbamoyl]pyridin-3-yl]oxypropan-2-yl]-1,3-oxazole-2-carboxamide Chemical compound C[C@H](NC(=O)c1ncco1)[C@H](Oc1ccc(nc1)C(=O)N[C@H]1CCCN(C1)C(=O)[C@H]1COC(=O)C1)c1ccc(cc1)C1CC1 WXZCDISWKXRJCU-FRLNKARYSA-N 0.000 claims description 3
- ROYGPEVBHHDUAZ-ZSOQJEKZSA-N N-[(1R,2S)-1-(4-cyclopropylphenyl)-1-[6-[[(3S)-1-[(3R)-5-oxooxolane-3-carbonyl]piperidin-3-yl]carbamoyl]pyridin-3-yl]oxypropan-2-yl]-1,3-oxazole-5-carboxamide Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C1=CN=CO1)OC=1C=NC(=CC=1)C(N[C@@H]1CN(CCC1)C(=O)[C@H]1COC(C1)=O)=O ROYGPEVBHHDUAZ-ZSOQJEKZSA-N 0.000 claims description 3
- YINDANZSOYUWKB-ZSOQJEKZSA-N N-[(1R,2S)-1-(4-cyclopropylphenyl)-1-[6-[[(3S)-1-[(3R)-5-oxooxolane-3-carbonyl]piperidin-3-yl]carbamoyl]pyridin-3-yl]oxypropan-2-yl]-1,3-thiazole-4-carboxamide Chemical compound C[C@H](NC(=O)c1cscn1)[C@H](Oc1ccc(nc1)C(=O)N[C@H]1CCCN(C1)C(=O)[C@H]1COC(=O)C1)c1ccc(cc1)C1CC1 YINDANZSOYUWKB-ZSOQJEKZSA-N 0.000 claims description 3
- GIMIATSROSJVCA-OADIUAHWSA-N N-[(1R,2S)-1-(4-cyclopropylphenyl)-1-[6-[[(3S)-1-[(3R)-5-oxooxolane-3-carbonyl]piperidin-3-yl]carbamoyl]pyridin-3-yl]oxypropan-2-yl]-3-methyl-1,2-oxazole-5-carboxamide Chemical compound C[C@H](NC(=O)c1cc(C)no1)[C@H](Oc1ccc(nc1)C(=O)N[C@H]1CCCN(C1)C(=O)[C@H]1COC(=O)C1)c1ccc(cc1)C1CC1 GIMIATSROSJVCA-OADIUAHWSA-N 0.000 claims description 3
- VAELWSLNTRVXQS-UHFFFAOYSA-N 1,3-oxazole-4-carboxamide Chemical compound NC(=O)C1=COC=N1 VAELWSLNTRVXQS-UHFFFAOYSA-N 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- WEOSIXASQDTFJY-BONVTDFDSA-N 4-[(1R,2S)-1-(4-bromophenyl)-2-[(2,2,2-trifluoroacetyl)amino]propoxy]benzoic acid Chemical compound BrC1=CC=C(C=C1)[C@H]([C@H](C)NC(C(F)(F)F)=O)OC1=CC=C(C(=O)O)C=C1 WEOSIXASQDTFJY-BONVTDFDSA-N 0.000 claims 1
- LRCLYAHQRMDJFF-XPTSAGLGSA-N 5-[(1R,2S)-1-(4-bromophenyl)-2-[(2,2,2-trifluoroacetyl)amino]propoxy]pyridine-2-carboxylic acid Chemical compound BrC1=CC=C(C=C1)[C@H]([C@H](C)NC(C(F)(F)F)=O)OC=1C=CC(=NC=1)C(=O)O LRCLYAHQRMDJFF-XPTSAGLGSA-N 0.000 claims 1
- UJEFRDIMXMYZRC-ZBEGNZNMSA-N C(C)C1=CC=C(C=C1)[C@H]([C@H](C)NC(C(F)(F)F)=O)OC=1C=CC(=NC=1)C(=O)O Chemical compound C(C)C1=CC=C(C=C1)[C@H]([C@H](C)NC(C(F)(F)F)=O)OC=1C=CC(=NC=1)C(=O)O UJEFRDIMXMYZRC-ZBEGNZNMSA-N 0.000 claims 1
- RTPYIXAIMBAMGM-XHDPSFHLSA-N C1(=CC=C(C=C1)[C@@H]([C@H](C)NC(C(F)(F)F)=O)OC=1C=CC(=NC=1)C(=O)O)C Chemical compound C1(=CC=C(C=C1)[C@@H]([C@H](C)NC(C(F)(F)F)=O)OC=1C=CC(=NC=1)C(=O)O)C RTPYIXAIMBAMGM-XHDPSFHLSA-N 0.000 claims 1
- RTPYIXAIMBAMGM-NHYWBVRUSA-N C1(=CC=C(C=C1)[C@H]([C@H](C)NC(C(F)(F)F)=O)OC=1C=CC(=NC=1)C(=O)O)C Chemical compound C1(=CC=C(C=C1)[C@H]([C@H](C)NC(C(F)(F)F)=O)OC=1C=CC(=NC=1)C(=O)O)C RTPYIXAIMBAMGM-NHYWBVRUSA-N 0.000 claims 1
- JRWZLMUWYMZEGW-GLGDSCIHSA-N C[C@@H]([C@@H](C1=CC=C(C2CC2)C=C1)OC(C=CC1)=CN1[C@@H]1CNCCC1)NC([C@@H]1OCCC1)=O Chemical compound C[C@@H]([C@@H](C1=CC=C(C2CC2)C=C1)OC(C=CC1)=CN1[C@@H]1CNCCC1)NC([C@@H]1OCCC1)=O JRWZLMUWYMZEGW-GLGDSCIHSA-N 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 claims 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- OZCHTJAVQGMIBV-ADSMNUKGSA-N N-[(1R,2S)-1-(4-cyclopropylphenyl)-1-[6-[[(3S)-piperidin-3-yl]carbamoyl]pyridin-3-yl]oxypropan-2-yl]-1,2-oxazole-3-carboxamide Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C1=NOC=C1)OC=1C=NC(=CC=1)C(N[C@@H]1CNCCC1)=O OZCHTJAVQGMIBV-ADSMNUKGSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 2
- FWIBCWKHNZBDLS-VKHMYHEASA-N (3s)-3-hydroxyoxolan-2-one Chemical compound O[C@H]1CCOC1=O FWIBCWKHNZBDLS-VKHMYHEASA-N 0.000 description 1
- FUDDLSHBRSNCBV-GSVOUGTGSA-N (4r)-4-hydroxyoxolan-2-one Chemical compound O[C@H]1COC(=O)C1 FUDDLSHBRSNCBV-GSVOUGTGSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
- VTPFDVQVZXROHP-BTYIYWSLSA-N 4-[(1R,2S)-1-(4-cyclopropylphenyl)-2-[(1-methylimidazole-2-carbonyl)amino]propoxy]benzoic acid Chemical compound C1(CC1)C1=CC=C(C=C1)[C@H]([C@H](C)NC(=O)C=1N(C=CN=1)C)OC1=CC=C(C(=O)O)C=C1 VTPFDVQVZXROHP-BTYIYWSLSA-N 0.000 description 1
- BIIGWHNGCZDFOS-ZSOQJEKZSA-N N-[(1R,2S)-1-(4-cyclopropylphenyl)-1-[6-[[(3S)-1-[(3R)-5-oxooxolane-3-carbonyl]piperidin-3-yl]carbamoyl]pyridin-3-yl]oxypropan-2-yl]-1,3-oxazole-4-carboxamide Chemical compound C[C@H](NC(=O)c1cocn1)[C@H](Oc1ccc(nc1)C(=O)N[C@H]1CCCN(C1)C(=O)[C@H]1COC(=O)C1)c1ccc(cc1)C1CC1 BIIGWHNGCZDFOS-ZSOQJEKZSA-N 0.000 description 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15185283 | 2015-09-15 | ||
| EP15185283.7 | 2015-09-15 | ||
| PCT/EP2016/071580 WO2017046096A1 (en) | 2015-09-15 | 2016-09-13 | Non-steroidal glucocorticoid receptor modulators for local drug delivery |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018528270A JP2018528270A (ja) | 2018-09-27 |
| JP2018528270A5 true JP2018528270A5 (enExample) | 2019-09-19 |
| JP6749399B2 JP6749399B2 (ja) | 2020-09-02 |
Family
ID=54145684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018532811A Active JP6749399B2 (ja) | 2015-09-15 | 2016-09-13 | 局所薬物送達のための非ステロイド性グルココルチコイド受容体モジュレーター |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10494363B2 (enExample) |
| EP (1) | EP3350175B1 (enExample) |
| JP (1) | JP6749399B2 (enExample) |
| KR (1) | KR20180050408A (enExample) |
| CN (1) | CN108368094B (enExample) |
| AU (1) | AU2016323254B2 (enExample) |
| CA (1) | CA2996819A1 (enExample) |
| CY (1) | CY1122592T1 (enExample) |
| DK (1) | DK3350175T3 (enExample) |
| ES (1) | ES2770303T3 (enExample) |
| HR (1) | HRP20200130T1 (enExample) |
| HU (1) | HUE048410T2 (enExample) |
| IL (1) | IL257549B (enExample) |
| LT (1) | LT3350175T (enExample) |
| MX (1) | MX374168B (enExample) |
| MY (1) | MY192275A (enExample) |
| PL (1) | PL3350175T3 (enExample) |
| PT (1) | PT3350175T (enExample) |
| RS (1) | RS60007B1 (enExample) |
| RU (1) | RU2731618C2 (enExample) |
| SA (1) | SA518391118B1 (enExample) |
| SI (1) | SI3350175T1 (enExample) |
| TW (1) | TWI733696B (enExample) |
| UA (1) | UA120980C2 (enExample) |
| WO (1) | WO2017046096A1 (enExample) |
| ZA (1) | ZA201801306B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2980934T3 (es) | 2019-01-22 | 2024-10-03 | Akribes Biomedical Gmbh | Modificadores selectivos del receptor de glucocorticoides para tratar la cicatrización alterada de heridas en la piel |
| CN116535324A (zh) * | 2023-07-07 | 2023-08-04 | 广东嘉博制药有限公司 | 一种苏式构型盐酸甲氧明的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL146057A (en) * | 2000-10-27 | 2007-09-20 | Pfizer Prod Inc | A process for the preparation of modulators of a non-steroidal glucocorticoid receptor |
| TWI370129B (en) * | 2005-02-14 | 2012-08-11 | Msd Oss Bv | Non steroidal glucocorticoid receptor modulators |
| JO2754B1 (en) * | 2006-12-21 | 2014-03-15 | استرازينكا ايه بي | Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders |
| AP2411A (en) * | 2007-02-02 | 2012-05-30 | Pfizer Prod Inc | Tricyclic compounds and their use as glucocorticoid receptor modulators |
| TW200951114A (en) | 2008-05-20 | 2009-12-16 | Astrazeneca Ab | Phenyl or pyridinyl substituted indazoles derivatives |
| KR101925955B1 (ko) * | 2011-03-18 | 2018-12-06 | 코어셉트 쎄라퓨틱스, 잉크. | 피리미딘 사이클로헥실 글루코코르티코이드 수용체 조절제 |
-
2016
- 2016-09-13 HR HRP20200130TT patent/HRP20200130T1/hr unknown
- 2016-09-13 CA CA2996819A patent/CA2996819A1/en active Pending
- 2016-09-13 HU HUE16775485A patent/HUE048410T2/hu unknown
- 2016-09-13 RS RS20200107A patent/RS60007B1/sr unknown
- 2016-09-13 RU RU2018113438A patent/RU2731618C2/ru active
- 2016-09-13 LT LTEP16775485.2T patent/LT3350175T/lt unknown
- 2016-09-13 KR KR1020187010532A patent/KR20180050408A/ko not_active Withdrawn
- 2016-09-13 PT PT167754852T patent/PT3350175T/pt unknown
- 2016-09-13 CN CN201680066622.1A patent/CN108368094B/zh active Active
- 2016-09-13 MY MYPI2018701015A patent/MY192275A/en unknown
- 2016-09-13 SI SI201630622T patent/SI3350175T1/sl unknown
- 2016-09-13 AU AU2016323254A patent/AU2016323254B2/en active Active
- 2016-09-13 US US15/759,622 patent/US10494363B2/en active Active
- 2016-09-13 ES ES16775485T patent/ES2770303T3/es active Active
- 2016-09-13 EP EP16775485.2A patent/EP3350175B1/en active Active
- 2016-09-13 JP JP2018532811A patent/JP6749399B2/ja active Active
- 2016-09-13 DK DK16775485.2T patent/DK3350175T3/da active
- 2016-09-13 UA UAA201804006A patent/UA120980C2/uk unknown
- 2016-09-13 MX MX2018003250A patent/MX374168B/es active IP Right Grant
- 2016-09-13 WO PCT/EP2016/071580 patent/WO2017046096A1/en not_active Ceased
- 2016-09-13 PL PL16775485T patent/PL3350175T3/pl unknown
- 2016-09-14 TW TW105129991A patent/TWI733696B/zh active
-
2018
- 2018-02-15 IL IL257549A patent/IL257549B/en active IP Right Grant
- 2018-02-26 ZA ZA2018/01306A patent/ZA201801306B/en unknown
- 2018-03-15 SA SA518391118A patent/SA518391118B1/ar unknown
-
2020
- 2020-02-06 CY CY20201100117T patent/CY1122592T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107624111B (zh) | 作为激酶抑制剂的杂环酰胺 | |
| RU2451674C2 (ru) | Пиридинкарбоксамиды в качестве ингибиторов 11-бета-hsd1 | |
| JP5311673B2 (ja) | Ｍｅｋ阻害剤の使用方法 | |
| JP2017530999A5 (enExample) | ||
| JP2019077725A5 (enExample) | ||
| RU2014142598A (ru) | Новые 4-метилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в | |
| EA013231B1 (ru) | Замещенные амидные производные в качестве ингибиторов протеинкиназы | |
| JP2009515814A5 (enExample) | ||
| JP2005526814A5 (enExample) | ||
| JP2016514711A5 (enExample) | ||
| WO2016027253A1 (en) | Heterocyclic amides as rip1 kinase inhibitors as medicaments | |
| RU2017116598A (ru) | Соединения и композиции для модуляции киназной активности мутантов egfr | |
| JP2014523851A5 (enExample) | ||
| NZ596071A (en) | Oxazole substituted indazoles as pi3-kinase inhibitors | |
| JP2010513288A5 (enExample) | ||
| JP2016523911A5 (enExample) | ||
| JP2019505595A5 (enExample) | ||
| JP2016540811A5 (enExample) | ||
| JP2016503009A5 (enExample) | ||
| WO2019130230A1 (en) | Heterocyclic amides as kinase inhibitors | |
| JP2016505557A5 (enExample) | ||
| US20150328188A1 (en) | Combination Therapies for the Treatment of Proliferative Disorders | |
| RU2015101102A (ru) | Гетероароматическое метильное производное циклического амина | |
| JP2018522929A5 (enExample) | ||
| JP2009514802A5 (enExample) |